-
April 27,2023E-nitiate Biopharmaceuticals Biologics Completes Series A Financing of 100 Million RMB In-depth layout around skin and autoimmune disease(hereinafter referred to as "QYB") announced the completion of a Series A financing round of 100 million RMB, led by Time Investment and followed by Taikun Fund, Linping State Investment and Hangzhou Golden Investment Industry Fund. This round of financing will be used to advance the clinical development of several pipelines, including QY201 and QY101, and further help the company expand its R&D pipeline.More
-
April 20,2022E-nitiate Biopharmaceuticals QY101 Ointment Was Approved for Clinical Trial in The Treatment of Atopic DermatitisRecently, E-nitiate Biopharmaceuticals received the"Drug Clinical Trial Approval Notice"issued by CDE (Notice No. : 2022LP00652,2022LP00653,2022LP00654,2022LP00655), QY101 ointment approved for clinical trial in the treatment of atopic dermatitis.More
-
December 10,2021E-nitiate Biopharmaceuticals Announces First 3 Subjects Dosed in Phase I Clinical Trial of QY201Recently, E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd. (hereinafter referred to as "E-nitiate Biopharmaceuticals") announced that the first dose of QY201 was given to 3 subjects in a phase I study. QY201 is an innovative drug for the treatment of atopic dermatitis developed independently by E-nitiate Biopharmaceuticals.More
-
October 29,2021E-nitiate Biopharmaceuticals QY201 Tablet Was Approved for Clinical Trial in The Treatment of Atopic DermatitisRecently, E-nitiate Biopharmaceuticals received the"Drug Clinical Trial Approval Notice"issued by CDE(Notice No. :2021LP01713), QY201 tablet was approved for clinical trial in the treatment of atopic dermatitis.More
-
December 11,2020New Project Dynamics | E-nitiate Biopharmaceuticals Settlement and Betta Fund Strategic Investment Signing Ceremony Successfully HeldOn December 10th, the signing ceremony of E-nitiate Biopharmaceuticals settlement and Betta fund strategic investment was successfully held in Yuhang District, Hangzhou. Zhu Zhenwei, member of the Standing Committee of Yuhang District Party committee, Secretary of the Party Working Committee and director of the Management Committee of the Development Zone, Dr. Ding lieming, chairman and CEO of Betta pharmaceutical and founder of Betta fund, and Dr. Shen Wang, chairman and chief scientist of E-nitiate Biopharmaceuticals attended the ceremony.More